A Phase 3 interventional study of Toripalimab and Pegaspargase in NK/T Cell Lymphoma Nos, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphoma, T-Cell · Sun Yat-sen University.
Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, this one is the only one that started in 2020, is one of 2 in phase 3, and was the 4th registered.
310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.
Browse Lymphoma, T-Cell studies →6 of the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
Sun Yat-sen University
Ages 18+
Sun Yat-sen University
Ages 18+
By country, each count listing its studies:
Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 207 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Median enrollment 55 across the 9 interventional studies, 450 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
1 of the studies in Lymphoma, T-Cell by Sun Yat-sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06733051Sun Yat-sen UniversityPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive toripalimab and induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given. Concurrent toripalimab of 240mg will be administered every 3 weeks for 3 cycles during IMRT. Toripalimab 240mg will be given every 3 weeks for 13 cycles, started on day 1 of induction chemotherapy.
Drug: Toripalimab · Drug: Pegaspargase · Drug: Gemcitabine · Drug: Oxaliplatin · Radiation: Definitive intensity-modulated radiotherapy (IMRT)
Patients will receive induction chemotherapy with pegaspargase, gemcitabine, oxaliplatin, every 3 weeks for 4 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) will be given.
Drug: Pegaspargase · Drug: Gemcitabine · Drug: Oxaliplatin · Radiation: Definitive intensity-modulated radiotherapy (IMRT)
toripalimab 240mg, d1, intravenous drip
pegaspargase, 2000U/m2, d1, intravenous drip
gemcitabine, 1000mg/m2, d1,d8, intravenous drip
oxaliplatin, 130mg/m2, d1, intravenous drip,
Definitive intensity-modulated radiotherapy (IMRT) of 54-56Gy will be given in 25\~26 days
progression free survival (PFS)
Time frame: 3 years
complete remission (CR) rate
Time frame: From the start of treatment with the interventions until 6 months
overall response rate (ORR)
Time frame: From the start of treatment with the interventions until 6 months
overall survival (OS)
Time frame: 3 years
recurrence-free survival (RFS)
Time frame: 3 years
event free survival (EFS)
Time frame: 3 years
disease-free survival (DFS)
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2020 (actual). Primary completion is estimated for Dec 2028, 103 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Toripalimab